Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo‐controlled trial

• DOI: 10.1111/dom.14516
• Publication Date: 2021-08-13T10:21:30Z
• Authors: Ida K. B. Rasmussen; Emilie H. Zobel; Rasmus S. Ripa; Bernt J. von Scho...; Viktor R. Curovic; Jacob K. Jensen; Andreas Kjaer; Tine W. Hansen; Peter Rossing
• Keywords: Clinical endpoint

Abstract Aim To test the hypothesis that treatment with liraglutide can reduce cardiac adipose tissue. Materials and methods LIRAFLAME is a randomized placebo‐controlled, double‐blind, parallel clinical study. Participants type 2 diabetes were to 1.8 mg/d or placebo for 26 weeks. Computed tomography was performed at baseline end of evaluate tissue volume, quantified automatically. We report results secondary endpoint evaluating changes in Results A total 102 participants randomly assigned (n = 51) 51). At baseline, mean (SD) volume comparable between group (232.6 [112.8] vs. 227.0 [103.2] mL; P 0.80). The change body weight −3.7 (−4.8, −2.6) kg −0.18 (−0.76, 0.40) group. From −11.5 (95% confidence interval −17.6, −5.4) mL ( < 0.001) −0.01 (−5.3, 5.3) 1.00) groups. reduction significantly greater compared (mean difference −11.4 [−19.4, −3.3] 0.006), but significance lost after adjustment mass index 0.46). Conclusion Treatment weeks associated placebo. not independent loss, suggesting this drug‐specific effect.